Schwann cell‐conditioned medium inhibits angiogenesis in vitro and in vivo

D Huang, JL Rutkowski, GM Brodeur… - … : The Official Journal …, 2000 - Wiley Online Library
D Huang, JL Rutkowski, GM Brodeur, PM Chou, JL Kwiatkowski, A Babbo, SL Cohn
Medical and Pediatric Oncology: The Official Journal of SIOP …, 2000Wiley Online Library
Background Neuroblastomas are biologically heterogeneous tumors that consist of two main
cell populations: neuroblastic/ganglionic cells and Schwann cells. The amount of
Schwannian stroma strongly impacts prognosis. Low tumor vascularity, localized stage, and
favorable outcome are associated with tumors that are Schwannian stroma‐rich/stroma‐
dominant. Procedure To investigate if Schwann cells play a role in inhibiting angiogenesis in
neuroblastoma tumors, we examined the ability of human Schwann cell‐conditioned …
Background
Neuroblastomas are biologically heterogeneous tumors that consist of two main cell populations: neuroblastic/ganglionic cells and Schwann cells. The amount of Schwannian stroma strongly impacts prognosis. Low tumor vascularity, localized stage, and favorable outcome are associated with tumors that are Schwannian stroma‐rich/stroma‐dominant.
Procedure
To investigate if Schwann cells play a role in inhibiting angiogenesis in neuroblastoma tumors, we examined the ability of human Schwann cell‐conditioned medium to affect bFGF‐ and VEGF‐induced endothelial cell proliferation and migration, and in vivo angiogenesis.
Results
Schwann cell‐conditioned medium significantly inhibited bFGF‐ and VEGF‐induced endothelial cell proliferation and migration. This effect appears to be specific for endothelial cells as smooth muscle cell and fibroblast proliferation were not inhibited by this medium. Schwann cell‐conditioned medium also inhibited in vivo angiogenesis in rat corneal assays.
Conclusions
Schwann cells produce a potent inhibitor(s) of angiogenesis that may be responsible for the low level of vascularity and more benign clinical behavior of Schwannian stroma‐rich/stroma‐dominant neuroblastoma tumors. Studies to identify the inhibitor(s) are ongoing. Med. Pediatr. Oncol. 35:590–592, 2000. © 2000 Wiley‐Liss, Inc.
Wiley Online Library